LRMRLarimar Therapeutics, Inc.Healthcare · Biotechnologyas of 2026-09-25
Horizon

Issued 2026-09-25 at $3.08 · now $3.08 (2026-09-25, +0.0% since)

Based on its own history, a month from the 2026-09-25 close, LRMR has typically landed between $2.13 and $4.53 — a range of −30.7% to +47.2% from the issuance price $3.08.

Range of outcomes in historically similar periods — not a price prediction. Ranges are scored publicly on /methodology.
  • Actual close
  • Typical path (median)
  • Middle 50% of outcomes
  • 90% range

3,062 overlapping 1 month windows · 2014-06-19 – 2026-08-26 · basis climatology · forecast (batch). Base rate up 53.7% (90% CI 51.5–55.9%, ≈1,391 obs). Not a call on this stock — we have no evidence its odds differ.

The cone is anchored at the 2026-09-25 issuance close ($3.08) — the price the forecast resolves against on 2026-10-26, not the latest close. The drawn path shape is illustrative (bands widen with √t); every labeled number is real — the anchor, the scored batch p90/IQR endpoints, and the typical move.

Where LRMR has typically landed a month from the 2026-09-25 close of $3.08 — the range is history, not a prediction.

$2.13worst · -30.7%$4.53best · +47.2%
  • now $3.08 (+0.0%)
  • typicalThe typical outcome — half of similar past periods did better and half did worse (not an average, so a few wild periods don't skew it). $3.01 (-2.2%)
  • middle 50%The central range of outcomes — half of similar past periods landed inside it, a quarter finished above, a quarter below. $2.51–$3.51
  • 90% rangeA nine-in-ten range — in about nine of every ten similar past periods the outcome stayed within these bounds. $2.13–$4.53
Actual 1-month windows behind the coneiEvery overlapping 1-month window in this security's own price history was ranked by realized return; shown are the 3 worst and 3 best of 3,062 windows spanning 2014-06-19 to 2026-09-25. Not cherry-picked — these are the extremes of the full sample. Max drop / max rise are the deepest and highest points reached within each window. See /methodology.
StartReturnMax dropMax rise
3 worst
2015-09-17−76.3%−76.3%+5.6%
2015-09-23−75.6%−76.3%+0.0%
2015-09-22−75.2%−76.1%+1.2%
3 best
2024-01-17+215.4%+0.0%+215.4%
2024-01-18+194.5%−1.8%+206.0%
2024-01-16+184.8%+0.0%+184.8%

3,062 overlapping windows · 2014-06-19 – 2026-09-25 · not cherry-picked

Pending catalysts

  • January 2027 — Trial primary completion: Phase 2 primary completion: An Open-Label Study of CTI-1601 in Subjects With Friedreich's Ataxia (source, as of 2026-08-14)

Public, scheduled events — dated attention, not a prediction of the outcome. See the FDA catalysts page for the historical base rate.

Seasonality · by month iHow this security has tended to do in each calendar month historically — a frequency, never a prediction.

iFor each calendar month, the share of years this security closed higher than the month before, and the average month-over-month return, over ~13 years of its own price history. Cells are shaded by average return. This is historical frequency, not a prediction — no month is a signal.
Jan
58%
+8.8%
n=12
Feb
58%
+9.0%
n=12
Mar
25%
−14.6%
n=12
Apr
33%
−3.4%
n=12
May
42%
−9.6%
n=12
Jun
50%
−0.4%
n=12
Jul
54%
−0.1%
n=13
Aug
46%
+7.5%
n=13
Sep
38%
−1.4%
n=13
Oct
67%
−2.9%
n=12
Nov
58%
+3.8%
n=12
Dec
58%
+5.1%
n=12

Up-frequency and average month-over-month return · historical frequency, not a prediction

Reported insider & political trades

Every Form 4 the people closest to this company have filed with the SEC — plotted against the share price, aggregated by month, and shown with the gap between when each trade happened and when it was disclosed. A public record, not advice.

Share price & reported tradesMonthly open-market valueReporting lag — trade date to filing date2026-092026-082026-072026-062026-052026-042026-032026-022026-012025-122025-112025-102025-092025-08$6$32026-07-06: 1 insider purchase, $167K — Hamilton Thomas Edward2026-02-27: 7 insider purchases, $25.6M — Flynn James E, Hamilton Thomas Edward, THOMAS FRANK E, SHERMAN JEFFREY W …2026-02: 7 open-market purchases, $25.6M2026-07: 1 open-market purchase, $167K↑ buys↓ salesdirector Hamilton Thomas Edward — Purchase on 2026-07-06, filed 2 days after the tradedirector Flynn James E — Purchase on 2026-02-27, filed 3 days after the tradedirector Flynn James E — Purchase on 2026-02-27, filed 3 days after the tradedirector Flynn James E — Purchase on 2026-02-27, filed 3 days after the tradedirector Flynn James E — Purchase on 2026-02-27, filed 3 days after the tradedirector Hamilton Thomas Edward — Purchase on 2026-02-27, filed 3 days after the tradedirector THOMAS FRANK E — Purchase on 2026-02-27, filed 3 days after the tradedirector SHERMAN JEFFREY W — Purchase on 2026-02-27, filed 3 days after the trade
DatePersonRoleActionShares @ priceValueOwnership Δvs S&P 1mvs S&P 6mOwned afterFiling
2026-07-06Hamilton Thomas EdwarddirectorPurchase50,000 @ $3.34$167K+7.5% of holding+22.3%not yet — horizon still open714,798Form 4 · filed 2 days after the trade
2026-02-27Flynn James EdirectorPurchase2,000,000 @ $5.00$10.0M+47.5% of holding−11.2%−37.2%6,207,982Form 4 · filed 3 days after the trade
2026-02-27Flynn James EdirectorPurchase1,084,012 @ $5.00$5.4M+11.4% of holding−11.2%−37.2%10,622,957Form 4 · filed 3 days after the trade
2026-02-27Flynn James EdirectorPurchase1,084,010 @ $5.00$5.4M+11.4% of holding−11.2%−37.2%10,622,928Form 4 · filed 3 days after the trade
2026-02-27Flynn James EdirectorPurchase831,978 @ $5.00$4.2M+11.4% of holding−11.2%−37.2%8,153,107Form 4 · filed 3 days after the trade
2026-02-27Hamilton Thomas EdwarddirectorPurchase100,000 @ $5.00$500K+17.7% of holding−11.2%−37.2%664,798Form 4 · filed 3 days after the trade
2026-02-27THOMAS FRANK EdirectorPurchase5,000 @ $5.00$25K+250.0% of holding−11.2%−37.2%7,000Form 4 · filed 3 days after the trade
2026-02-27SHERMAN JEFFREY WdirectorPurchase5,000 @ $5.00$25Kownership Δ n/a−11.2%−37.2%5,000Form 4 · filed 3 days after the trade
2025-07-31Flynn James EdirectorPurchase3,387,539 @ $3.20$10.8M+55.1% of holding+2.6%−7.8%9,538,945Form 4 · filed 4 days after the trade
2025-07-31Flynn James EdirectorPurchase3,387,529 @ $3.20$10.8M+55.1% of holding+2.6%−7.8%9,538,918Form 4 · filed 4 days after the trade
2025-07-31Flynn James EdirectorPurchase2,599,932 @ $3.20$8.3M+55.1% of holding+2.6%−7.8%7,321,129Form 4 · filed 4 days after the trade
2024-02-16Flynn James EdirectorPurchase1,430,206 @ $8.74$12.5M+30.3% of holding−36.3%−51.0%6,151,389Form 4 · filed same day
2024-02-16Flynn James EdirectorPurchase1,430,206 @ $8.74$12.5M+30.3% of holding−36.3%−51.0%6,151,406Form 4 · filed same day
2024-02-16Flynn James EdirectorPurchase1,430,205 @ $8.74$12.5M+51.5% of holding−36.3%−51.0%4,207,982Form 4 · filed same day
2024-02-16Hamilton Thomas EdwarddirectorPurchase57,208 @ $8.74$500K+11.3% of holding−36.3%−51.0%564,798Form 4 · filed 105 days after the trade

The vs-S&P columns are a labeled look-back on what the stock did after each filing, measured against the index over the same window. Descriptive history, not a claim about the person or a reason to trade.

34 award / exercise / gift records — not counted as purchases

Awards, option exercises, gifts and tax-withholding disposals are shown separately and never counted as open-market purchases or sales — they carry no conviction information.

DatePersonRoleActionSharesOwned afterFiling
2026-05-19Flynn James EdirectorAward / grant55,15055,150Form 4
2026-05-19LEFF JONATHAN SdirectorAward / grant55,15055,150Form 4
2026-05-19THOMAS FRANK EdirectorAward / grant55,15055,150Form 4
2026-05-19Truitt JosephdirectorAward / grant55,15055,150Form 4
2026-05-19SHERMAN JEFFREY WdirectorAward / grant55,15055,150Form 4
2026-05-19Hamilton Thomas EdwarddirectorAward / grant55,15055,150Form 4
2026-01-26BEN-MAIMON CAROLEdirectorAward / grant600,600600,600Form 4
2026-01-26Celano MichaelofficerAward / grant37,604215,785Form 4
2026-01-26Celano MichaelofficerAward / grant225,622225,622Form 4
2026-01-26Clayton RussellofficerAward / grant153,822153,822Form 4
2026-01-26Shankar GopiofficerAward / grant25,63776,443Form 4
2026-01-26Shankar GopiofficerAward / grant153,822153,822Form 4
2026-01-26Clayton RussellofficerAward / grant25,63771,443Form 4
2026-01-26BEN-MAIMON CAROLEdirectorAward / grant100,100368,276Form 4
2025-05-13THOMAS FRANK EdirectorAward / grant19,00019,000Form 4
2025-05-13Truitt JosephdirectorAward / grant19,00019,000Form 4
2025-05-13Flynn James EdirectorAward / grant19,00019,000Form 4
2025-05-13LEFF JONATHAN SdirectorAward / grant19,00019,000Form 4
2025-05-13Hamilton Thomas EdwarddirectorAward / grant19,00019,000Form 4
2025-05-13SHERMAN JEFFREY WdirectorAward / grant19,00019,000Form 4
2025-01-22Clayton RussellofficerAward / grant139,838139,838Form 4
2025-01-22BEN-MAIMON CAROLEdirectorAward / grant546,000546,000Form 4
2025-01-22BEN-MAIMON CAROLEdirectorAward / grant91,000387,208Form 4
2025-01-22Celano MichaelofficerAward / grant34,185178,181Form 4
2025-01-22Celano MichaelofficerAward / grant205,111205,111Form 4
2025-01-22Shankar GopiofficerAward / grant23,30650,806Form 4
2025-01-22Shankar GopiofficerAward / grant139,838139,838Form 4
2025-01-22Clayton RussellofficerAward / grant23,30645,806Form 4
2024-05-29Flynn James EdirectorAward / grant19,00019,000Form 4
2024-05-29Hamilton Thomas EdwarddirectorAward / grant19,00019,000Form 4
2024-05-29THOMAS FRANK EdirectorAward / grant19,00019,000Form 4
2024-05-29Truitt JosephdirectorAward / grant19,00019,000Form 4
2024-05-29SHERMAN JEFFREY WdirectorAward / grant19,00019,000Form 4
2024-05-29LEFF JONATHAN SdirectorAward / grant19,00019,000Form 4

Source: SEC Form 4 filings. Each row links to its original filing.

Across 2012–2021, stocks where a CEO, C-suite officer, or director had recently made an open-market common-stock purchase ran about +28 bp per month above the universe average (n=34,268 stock-weeks). A historical tendency, not a prediction.

Congressional disclosures

No congressional trades disclosed for this company.

Research tool, not investment advice — historical frequencies, not recommendations. A product of Marovel Technologies LLC. Full terms.